Posted on 30/11/2009 in Pharmaceutical Company Product News Sanofi-aventis drug Multaq (dronedarone 400mg Tablets) - which is indicated for use in patients with current non-permanent atrial fibrillation (AF) - has been approved for use by the European commission (EC).
The EC has granted marketing authorisation for Multaq in all 27 European Union member states following the positive opinion issued in September by the Committee for Medicinal Products for Human Use of the European Medicines Agency.
It is indicated in clinically stable adult patients with a history of AF to prevent its recurrence.
Multaq is the first anti-arrhythmic drug approved on the continent to have demonstrated the ability to reduce cardiovascular hospitalisations or death from AF.
Marc Cluzel, executive vice-president of research and development at Sanofi-aventis, commented: "The approval of Multaq is the result of more than 15 years of research and development conducted by Sanofi-aventis and supported by the commitment of the experts involved."
This news comes after the firm announced last week that it has forged a partnership with Medicines for Malaria, which will see the organisations collaborate to launch the largest study into the effects of an antimalarial drug.
Other news stories from 30/11/2009
Read more in the Zenopa News Archive
How this news is generated
|
